Trial Profile
(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia [EXTENSION OF 700215781]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms OSKIRA-Asia-1X
- Sponsors AstraZeneca
- 30 Nov 2020 Results assessing efficacy (OSKIRA-Asia-1: NCT01569074) and long-term safety/tolerability (OSKIRA-Asia-1X), published in the Rheumatology.
- 01 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Mar 2013 New trial record